Our weekly newsletter includes a summary of the latest TAG activities, key Australian and international reports and publications, medication safety, papers of interest, consultations and upcoming events.
The New South Wales Therapeutic Advisory Group Inc. (NSW TAG) is an independent, not-for-profit member-based organisation, comprised of clinical pharmacologists, pharmacists, nurses and clinicians committed to promoting quality use of medicines (QUM) in NSW public hospitals and the wider community.
We aim to provide consumers of pharmaceutical health care in NSW with the most appropriate medicines in the most appropriate manner whilst ensuring that the limited resources of the health care budget devoted to medicines use are used according to sound economic principles.
In pursuing this goal, we focus on providing information, advice and support to decision-makers in NSW public hospitals, NSW Ministry of Health and other relevant organisations.
16th February 2017
These Guiding Principles have been developed to assist NSW hospitals, local health districts and specialty health networks implementing electronic medication management systems (eMeds) to expand their existing medication management governance processes to incorporate safe and effective eMeds design, use and ongoing optimisation. They aim to provide a framework that enables DTCs and hospital/district executive to develop a flexible and scalable model of eMeds clinical governance, whilst continuing the oversight of medicines management that is not related to eMeds.
9th February 2017
Our Optimising timely access to life-saving drugs across NSW, the ACT and beyond is now available.
8th February 2017
Our Revitalising hospital evaluation of medicines use - the case for DUE is now available.
14th September 2016
The Opioid Skin Patches are High Risk Medicine practical guidance is now available.
The Patient self-funding offers to access medicines: Drug and Therapeutic Committee considerations discussion paper is now available.
8 February 2017
The following email discussions are now available to members:
- Off-label use of rituximab in membranous nephropathy